Calibr-Skaggs Announces Expansion Of Option And License Agreement With AbbVie To Develop Novel Cell Therapies; AbbVie Will Pay Calibr-Skaggs An Upfront License Fee And Maintain Exclusive Access To Their Switchable Car-T Platform For A Term Of Upto 5-Years
Portfolio Pulse from Benzinga Newsdesk
AbbVie expands its collaboration with Calibr-Skaggs to further explore the switchable CAR-T (sCAR-T) platform for solid tumor and autoimmune disease treatments. AbbVie will pay an upfront license fee for exclusive access to the sCAR-T platform for up to five years, with options to license existing cell therapy programs. Calibr-Skaggs will support discovery of next-generation sCAR-Ts, with potential milestone payments and royalties.
February 06, 2024 | 5:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AbbVie secures exclusive access to Calibr-Skaggs' sCAR-T platform, aiming to develop novel cell therapies for solid tumors and autoimmune diseases. The deal includes an upfront license fee, potential milestone payments, and royalties.
AbbVie's expanded collaboration with Calibr-Skaggs for exclusive access to the sCAR-T platform signifies a strategic move to strengthen its position in oncology and immunology. The financial commitment and potential for innovative treatments likely to have a positive short-term impact on investor sentiment and AbbVie's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90